atugen and Sankyo Sign Multi-Year Contract Research Agreement

20-May-2004

Berlin, Germany. atugen AG announced that it has signed a multi-year contract research agreement with Sankyo Co. Ltd, one of Japan's leading pharmaceutical companies. Both companies have already successfully collaborated on a number of proprietary molecular targets that Sankyo has discovered in different disease areas. atugen will now use its gene silencing technologies, including siRNA, GeneBlocs®, delivery reagents and functional assays to validate an undisclosed number of Sankyo targets

No financial details of the research agreement are being disclosed.

"We are delighted to be starting on this major research project with Sankyo. We have already worked with the company on a pilot study so our two research teams have established a working routine," said Dr. Klaus Giese, atugen´s Chief Scientific Officer and Vice President of Research. "Our knowledge and experience in target validation and disease pathways will save considerable time for Sankyo by validating targets that will lead to the most viable drugs."

Other news from the department business & finance

These products might interest you

Blotting standards and reagents

Blotting standards and reagents by Cytiva

Western blotting standards and reagents

Blotting the course to effective detection of proteins from sample preparation to analysis

reagents
Micro-Dx™ CE IVD

Micro-Dx™ CE IVD by Molzym

Fully automated from sample to PCR analysis

Rapid identification of bacteria and fungi without time-consuming cultivation

DNA extraction kits
DNA-free Taq Polymerases and Mastermixes

DNA-free Taq Polymerases and Mastermixes by Molzym

DNA-free reagents for unrivalled sensitivity in molecular biology

Purity that makes the difference

PCR accessories
Greener Alternative Products

Greener Alternative Products by Merck

Sustainable laboratory products for environmentally conscious research

Over 2,500 ecological alternatives to reduce your laboratory footprint

consumables
Loading...

Most read news

More news from our other portals